AI Article Synopsis
- Patients with septic shock can face high mortality rates if they have low blood pressure that doesn't respond to treatments like fluids and high-dose noradrenaline.
- Guidelines recommend adding a second vasopressor, like vasopressin, if noradrenaline is exceeding 0.5 µg/kg/min.
- Angiotensin II has shown promise in improving blood pressure in these patients and this review explores its effectiveness and the specific patient groups that might benefit the most from this treatment.
Article Abstract
Patients with septic shock who experience refractory hypotension despite adequate fluid resuscitation and high-dose noradrenaline have high mortality rates. To improve outcomes, evidence-based guidelines recommend starting a second vasopressor, such as vasopressin, if noradrenaline doses exceed 0.5 µg/kg/min. Recently, promising results have been observed in treating refractory hypotension with angiotensin II, which has been shown to increase mean arterial pressure and has been associated with improved outcomes. This narrative review aims to provide an overview of the pathophysiology of the renin-angiotensin system and the role of endogenous angiotensin II in vasodilatory shock with a focus on how angiotensin II treatment impacts clinical outcomes and on identifying the population that may benefit most from its use.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10882873 | PMC |
| http://dx.doi.org/10.1186/s44158-024-00150-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!